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Metabolic considerations of the portal circulation 
In the last 20 years, understanding has evolved about 
what has become known as the 'hepatotrophic' concept. 
The hepatotrophic hypothesis holds that there are specific 
substances in the portal venous blood, not found in equal 
concentration in other kinds of blood, which are important 
for the maintenance of normal hepatic morphology, func-
tion, and the capacity for regeneration (Starzl & 
Terblanche 1979). 
Hypotheses are usually formulated to explain obser-
vations that are otherwise incomprehensible, and so it was 
with the suggestion that portal venous blood contains 
hepatotrophic substances. The phenomena that required 
explanation were those which followed completely 
diverting portacaval shunt (Eck's fistula). 
THE ENIGMA OF ECK'S FISTULA 
When the Russian surgeon, Nicholas Eck, described his 
technique and experience with end-to-side portacaval 
shunt in dogs, he was convinced that the procedure was 
harmless, and that it would find clinical application for the 
treatment of patients with intractible ascites (Eck 1877). 
These hopes were dampened by Pavlov, the great St. 
Petersburg physiologist, and his associates who demon-
strated liver atrophy, fatty infiltration, and other striking 
abnormalities in livers deprived of portal blood flow by 
completely diverting portacaval shunt (Hahn et al 1893). 
Furthermore, they noted in their dogs the almost in-
variable development of weight loss, alopecia, and a 
progressive neurological disorder which premonitored 
death. The complex neurological manifestations were 
called 'meat intoxication' because they could be precipi-
tated with a high protein diet. The later work of 
McDermott et al (1954), showed that the syndrome was 
associated with elevations in blood ammonia, and it is now 
established that the canine disease was the analogue of 
hepatic encephalopathy in humans. 
It was obvious that something taken from the blood 
supply of the liver was the explanation for the devastating 
anatomical and physiological changes which resulted from 
Eck fistula. Whether the loss of specific substance(s) 
contained in the portal blood (the qualitative theory) was 
responsible or if these consequences simply followed from 
a reduction of the total hepatic blood flow (the flow 
hypothesis) was disputed for decades. The dispute did not 
qualify as a great debate since there was so little movement 
on both sides over long periods of time as summarized in 
a recent monograph (Starzl et al 1983b) and because 
publications favouring the flow hypothesis by Mann 
(1944), Child et al (1953) and Fischer et al (1954) and their 
associates were not challenged. Yet, scepticism remained. 
As late as 1961, Bollman, one of the foremost students of 
experimental hepatic surgery, wrote, 'In the 83 years since 
it was first reported, the Eck fistula has been reasonably 
successful in hiding its secrets as well as giving rise to 
many additional questions fundamental to an under-
standing of the functions of the intestine, liver, and brain.' 
THE MODERN EXPERIMENTS 
The double liver models 
Within two years after Bollman wrote those words, 
inquiries were begun which laid bare the secrets of the Eck 
fistula. The experiments were originally designed to deter-
mine the optimal techniques for revascularization of 
auxiliary liver homografts. It was hoped that such extra 
livers could be transplanted to a heterotopic location in 
humans without disturbing the diseased native liver. When 
auxiliary dog livers were placed in the paravertebral gutter, 
given an hepatic arterial supply, and provided with a portal 
venous inflow from the inferior vena cava (Fig. 115.1), the 
extra livers atrophied with astonishing speed (Starzl et al 
1964). The atrophy could be reduced or prevented if the 
homografts were provided with portal inflow from the 
recipient splanchnic venous system (Marchioro et al 1965). 
In subsequent experiments (Marchioro et al 1967), the 
same interactions were demonstrated between two portions 
of the dog's own liver in which the only physiological vari-
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Fig. 115.1 Auxiliary liver transplantation in dogs. Note that lh<.: 
reconstituted portal blood supply is from the distal inferior vena cava. 
D = duodenum; CIA = common iliac artery; PV = portal vein; IVC 
= inferior vena cava. Note donor liver placed below the renal vessels. 
Reproduced with permission from Starzl et al 1964 
able was the kind of venous inflow directed into the right 
and left portal vein branches (Fig. 115.2). The liver frag-
ment given normal splanchnic flow hypertrophied and 
underwent hyperplasia compared to the atrophic portion 
nourished with high flow systemic venous or arterial hlood 
(Marchioro et al 1967, Starzl et al 1973b). It was evident 
from such 'split liver' preparations that some substance(s) 
present in the portal venous blood which was vital for the 
health of the liver was being efficiently extracted by the 
liver tissue to which the splanchnic venous blood was first 
exposed, thus becoming unavailable for the other liver or 
liver fragment. When venous blood from the splanchnic 
system was subdivided in another kind of split liver exper-
iment (Fig. 115.3), the venous effluent from the pancreas 
had better hepatotrophic qualities than that from the intes-
tines (Starzl et al 1973 b), an advantage that was reduced 
or eliminated with pancreatectomy or the production of 
alloxan diahetes (Fig. 115.3) (Starzl et al 1975a, b, c). 
Thus, the circumstantial evidence had become strong that 
the elusive substance m portal venous blood was 
endogenous insulin. 
Fig. 115.2 The operation of partial (split) transposition in dogs. Note 
that one of the main portal veins (left in A, right in B) retains the 
natural splanchnic flow and that the other one receives the total input 
of the suprarenal inferior vena cava. PV = portal vein; L = left 
branch portal vein; R -- right branch portal vein; IVC = inferior vena 
cava. Reproduced with permission from Marchioro et al 1967 
Hormone infusion experiments 
In 1975, the insulin theory was tested directly (Starzl et 
al 1976). Dogs with portacaval shunt had insulin infused 
directly into one of the tied-off main portal vein branches 
(Fig. 115.4). In the infused lobes, this simple expedient 
prevented the liver cell atrophy and multiple ultra-
structural changes in the hepatocytes which follow Eck 
fistula and which were present in the contralateral uninfused 
liver lobes. 
Evisceration experiments 
The importance of insulin as a hepatotrophic substance 
was further emphasized with extirpation of various 
splanchnic viscera including the pancreas (Starzl et al 
1978a, b). In all of the double liver, infusion and eviscer-
ation experiments, other minor but cumulatively important 
hepatotrophic effects were observed independent of 
insulin, but none had the potency and significance of 
insulin. 
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Fig. 115.3 Splanchnic division experiments. In these dogs, the right liver lobes received venous return from the pancreaticogastroduodenosplenic 
region, and the left liver lobes received venous blood from the intestines. A = non-diabetic dogs; B = alloxan-induced diabetic dogs; e = dogs with 
total pancreatectomy. Reproduced with permission from Starzl et al197Sb 
Insulin 
Fig. 115.4 Experiments in which Eck's fistula is constructed and 
postoperative infusions of hormones are made into the left portal vein 
R = right portal branch; L = left portal branch; Ive = inferior vena 
cava 
THE IMPLICATIONS OF ORGANELLE CHANGES 
For a long time, it was assumed that the histopathological 
changes caused by portacaval shunt in dog livers were 
species specific. However, it has become obvious that the 
resulting changes in the liver are much the same in 
rodents, dogs, swine, sub-human primates and humans 
(Putnam et al 1976). Furthermore, the atrophy proceeds 
with surprising speed, being 90% complete in dogs within 
three or four days (Starzl et al 1976). 
With the development of electron microscopic tech-
niques, many observers, whose work is summarized else-
where (Starzl et al 1983b), described the sweeping changes 
in hepatocyte organelles which paralleled the atrophic 
changes in the rapidity of their development. The most 
specific alterations were depletion and disruption of the 
rough endoplasmic reticulum (RER) and reduction in the 
membrane-bound polyribosomes. Since RER is the 
'factory' of the cell (Fawcett 1981, Jones et al 1966), a 
consequent reduction in many hepatic biosynthetic 
processes would be expected. 
THE BIOCHEMICAL POINT-OF-VIEW 
Numerous studies summarized elsewhere (Starzl et al 
1983b) have verified the foregoing expectations and have 
illustrated the spectrum of changes in hepatic function that 
may be expected after portacaval shunt. The effort of 
portal diversion on hepatic lipid metabolism has been 
unusually well studied. Reductions occur in the synthesis 
of cholesterol, triglycerides, and other moieties including 
the low-density lipoproteins which are responsible for the 
transport of endogenous cholesterol. Other synthetic path-
ways that are depressed by Eck fistula in experimental 
animals include those of bile acid metabolism as well as the 
hepatic urea (Krebs-Henseleit) cycle. 
As detailed studies are made of other hepatic synthetic 
or metabolic processes after portacaval shunt, it will not 
be surprising if all are found to follow the same pattern. 
This possibility has been supported by many studies during 
the last 15 years, (Starzl et al 1983 b), that have shown 
how portacaval shunt lowers the activity of the hepatic 
microsomal mixed-function enzyme system. This enzyme 
system, for which multiple cytochrome P-4S0 and P-448 
species serve as terminal oxidases, is central to the metab-
olism of a variety of drugs and chemicals as well as of 
endogenous compounds such as steroids and fatty acids. 
Thus, depression of this enzyme system predictably will 
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cause enormous numbers of subtle and profound metabolic 
effects after portal diversion. 
It is rare in biological systems to have concepts as simple 
as the role of insulin as the principal hepatotrophic factor 
in portal venous blood. Substances other than insulin are 
also hepatotrophic and have a significant cumulative affect. 
However, no single factor rivals insulin in importance. 
Thus, it is not surprising that ultra-structural changes 
identical to those caused by Eck fistula can be induced in 
the livers of rats by the simple expedient of producing 
alloxan diabetes (Reaven et al 1973). Similarly, Kato 
(1977) has shown that the activity of the mixed-function 
oxidase system is depressed in rats after alloxan-induced 
diabetes in exactly the same way as it is depressed by 
portacaval shunt. 
THE USE OF PORTACAVAL SHUNT FOR 
METABOLIC OBJECTIVES IN HUMANS 
The changes in metabolism caused by portacaval shunt 
have been exploited to treat three inborn errors of metab-
olism. In essence, the hepatic injury caused by portacaval 
shunt and the consequent metabolic perturbations have 
been used to offset the even greater morbidity caused by 
the inborn error. 
Glycogen storage diseases 
Type 1 glycogen storage disease (GSD) was the first 
inborn error of metabolism to be defined in terms of a 
specific enzyme defect (glucose-6-phosphatase). In Type 3 
GSD, hepatic amylo-l,6-glucosidase is deficient and in 
Type 6 disease, phosphorylase is deficient. When porta-
caval shunt was used to treat the glycogen storage diseases 
more than 20 years ago (Starzl et al 1965), the rationale 
was that if splanchnic venous blood was short-circuited 
around the liver, alimentarv glucose would be made more 
readily available to peripheral tissues. It was envisioned 
that hypoglycaemia would be relieved thereby and that 
glycogen deposition would be slowed in the liver, which 
would no longer be presented with such a heavy glucose 
load at each meal. As already described, the consequences 
of portacaval shunt were more subtle and wide-ranging 
than that simplistic view suggested (Starzl et al 1973c, 
1983b). 
After portal diversion, most of the children who had 
pre-existing hypoglycaemia did not have relief of this 
symptom or else the relief was not complete (Starzl et al 
1973c, 1983b). However, all of the patients underwent 
major growth spurts, the hepatomegaly was usually 
relieved, the hyperlipidaemia which is characteristic of 
Type 1 disease was profoundly and permanently reduced, 
and correction of other metabolic problems including 
abnormal bleeding, uric acid elevations and abnormal 
calcium metabolism was observed (Starzl et al 1973c, 
Starzl et al 1983b). These palliative effects were obtained 
with an acceptable morbidity although at least one of the 
10 children treated developed evidence of hepatic encepha-
lopathy (Starzl et al 1983b). 
Portacaval shunt for the treatment of GSD was virtually 
abandoned after it was found that contino us night-
feeding, as advocated by Greene et al (1976), could achieve 
the same beneficial effects without the threat of encepha-
lopathy. In intractable cases, it may be that liver trans-
plantation should be offered as the first operation, since 
complete correction of Type 1 glycogen storage disease has 
been achieved with liver replacement by Malatack et al 
(1983). The recipient, who had been treated with an end-
to-side portacaval shunt eight years previously, has had 
essentially normal carbohydrate metabolism from within 
a few minutes after revascularization of her new liver until 
the present time, almost three vears later. 
Familial hypercholesterolaemia (FH) 
Patients with the disease of FH have an absence or de-
ficiency of cell membrane low density lipoprotein (LDL) 
receptors. Because of this, they cannot catabolize 
endogenous cholesterol normally and they lack a 'switch-
off' mechanism to control lipid (especially cholesterol) 
synthesis (Goldstein et al 1983). Patients who have the 
homozygous genetic trait are notoriously resistant to all 
forms of conventional therapy and, until recently, end-to-
side portacaval shunt has been the most effective method 
of reducing serum cholesterol levels (Starz1 et al 1973a, 
1983a). In a series of the author's own patients, as well as 
in patients treated elsewhere with portal diversion, total 
serum cholesterol concentrations have almost always 
declined from 20 to 60% (average about 350ft) after porta-
caval shunt (Starz1 et al 1983a). This decline usually is 
maintained permanently. 
The mechanisms which cause lipid lowering in such 
patients are qualitatively similar to those in experimental 
animals discussed above, namely a reduction in the hepatic 
synthesis of cholesterol and other lipids. In a number of 
patients whose lipid metabolism was studied before and 
after portacaval shunt, cholesterol and LDL synthesis was 
greatly reduced along with that of bile acids. The most 
significant finding was the reduction of total body choles-
terol mass by one half or more over a period of 12-18 
months (McNamara et al 1982). With such data, it has not 
been hard to explain the extraordinary shrinkage or disap-
pearance of tendinocutaneous xanthomas which are charac-
teristically found in such patients (Starzl et al 1973a, 1974, 
1983a) (Fig. 115.5). 
In spite of its striking benefits to patients with homo-
zygous FH, portacaval shunt has been only palliative. The 
palliation has been incomplete, since normal serum chol-
esterol values have not been achieved in any patient with 
A 
B 
Fig. 115.5 The hands of a patient with hyperlipidaemia two weeks 
before (A) and 16 months afte r (B) portacaval shunt. Reproduced 
with permission from Starzl e t al 1974 
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homozygous disease. The usual finding has been for serum 
cholesterol concentrations to drop from the range of 1000 
to 600 mg% or from the 800 range to 500 mg%, etc. The 
new levels have been too high to allow the routine control 
or reversal of the cardiovascular complications of the 
disease. 
The observations and experience with portacaval shunt 
for FH have subtly influenced the perception of the patho-
genesis of this disorder. Previously , it was suspected that 
FH was a pancellular disease in which the deficiency of 
LDL receptors throughout the body was responsible for 
the runaway cholesterol synthesis. When it was realized 
that portacaval shunt had such a drastic affect on serum 
cholesterol metabolism, it became almost certain that the 
liver played a far more central role in cholesterol metab-
olism than had been appreciated, and it was suggested that 
liver transplantation might be curative (Starzl et al 1983a). 
A number of other studies have supported the hypothesis 
of hepatic control of cholesterol metabolism (Goldstein et 
al 1983). In early 1984, a child with homozygous FH 
whose heart had been destroyed by cholesterol deposits 
was treated by liver transplantation at the same time as the 
heart was replaced. The serum cholesterol levels were 
reduced about 70% from 1000 mg% to below 300 mg%, 
at the same time as rapid reabsorption of her tendino-
cutaneous xanthomas occurred (Starzl et al 1984). Thus, as 
with glycogen storage disease, the most effective form of 
metabolic engineering in FH has been with the provision 
of a new liver. 
Alpha-I-antitrypsin deficiency 
In this disease , the liver produces an abnormal alpha-l-
antitrypsin which cannot be effectively transported out of 
the hepatocytes. The entrapped alpha globulin apparently 
causes irritation that leads to hepatic cirrhosis, portal 
hypertension and hepatic failure (Hood et al 1980). 
We have performed end-to-side portacaval shunt in 
three children with the cirrhotic liver disease of alpha-l-
antitrypsin deficiency (Starzl et al 1983c). After follow-ups 
of six to nine years, the children are still alive. The possi-
bility that the liver damage of alpha-I-anti trypsin de-
ficiency had been slowed was supported by the 
histopathological studies of biopsy specimens obtained 
operatively and postoperatively in two of these patients. 
Many months after operation re-biopsy showed that the 
percentage of hepatocytes containing the alpha-I-anti-
trypsin globules was substantially reduced (Starzl et al 
1983c). 
Our speculation has been that portacaval shunt dimin-
ished the synthesis of the alpha-I-antitrypsin , presumably 
by altering the function of the RER and its ribosomes (see 
earlier) without commensurately reducing the transport of 
this alpha protein . With a better equilibrium between the 
production and excretion of the alpha-I-antitrypsin , it is 
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Fig. 115.6 Kinds of portal-systemic shunts: A. End-to-side shunt. B. Variety of side-to-side shunts: Bl = portal-caval; B2 = spleno-renal; B3 = 
interposition H. graft~mesenterico-caval; B4 = mesenterico-caval (Clatworthy). C. Selective portal-systemic shunts: Cl = distal spleno-renal; C2 = 
spleno-caval; C3 = coronary-caval 
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possible that its intracellular accumulation has been slowed 
or possibly even reversed. 
As with the two other inborn errors, the most effective 
way of treating alpha-I-antitrypsin deficiency has been 
with provision of a phenotypically normal liver (Hood et 
al 1980, Starzl et al 1982). This has been accomplished in 
several dozen patients, with the longest postoperative 
survival now being more than eight years. After the oper-
ation, the Pi (protease inhibitor) type of the recipient 
permanently becomes that of the phenotypically normal 
donor, and the depressed alpha-I-antitrypsin levels are 
promptly restored to normal. In future years, portacaval 
shunt to palliate alpha-I-antitrypsin deficiency will be 
rarely used if ever, whereas the direct and logical step of 
performing liver replacement will become common. 
PORTAL SYSTEMIC SHUNT FOR 
COMPLICATIONS OF PORTAL HYPERTENSION 
The inescapable conclusion from all of the work on the 
hepatotrophic concept in the last two decades, is that 
portal-systemic diversion is inherently harmful to the 
liver. Exploitation of portal diversion for its increasingly 
well understood metabolic effects has only contributed to 
suspicion about the use of portacaval shunt for mechanical 
and haemodynamic objectives. 
The kinds of portacaval shunts that have been used for 
haemodynamic objectives are shown graphically in Figure 
liS .6. As summarized elsewhere, there is good reason to 
believe that all of the side-to-side shunts (Fig. lIS.6B) 
result in complete diversion of the portal blood if they are 
made of adequate size, just as occurs with a straight-
forward end-to-side shunt (Fig. lIS.6A). In contrast, the 
selective shunts devised and popularized by Dean Warren 
and his associates in Atlanta, Georgia do compress oeso-
phageal varices while at the same time maintaining a 
substantial portion of residual hepatopetal flow. For this 
reason, the selective shunts in Figure lIS.6C are the most 
desirable physiologically. 
It has been disappointing that randomized trials 
comparing selective distal splenorenal versus totally 
diverting shunts have not revealed a striking divergence in 
the patient life survival curves. Nevertheless, the incidence 
of hepatic encephalopathy has been less in practically all 
of these trials (Starzl et al 1983b). If this trend continues, 
a better quality of life as opposed to mere survival may 
prove to be the only justification for the selective shunts. 
It will then have to be concluded that the survival curves 
are similar with the various kinds of surgical treatment, 
because patients with progressive hepatic diseases severe 
enough to warrant such decompressing procedures have a 
course so immutable that the relative merits of different 
kinds of palliative treatment cannot be accurately 
measured. 
HEPATOTROPHIC FACTORS IN REGENERATION 
It is almost certain that the same portal substances which 
regulate the size of hepatocytes and the function of these 
liver cells play an important role in at least permitting, or 
possibly even initiating, the cell renewal (regeneration) by 
which the liver restores itself to its original size after part 
of it has been removed. This subject has been reviewed 
elsewhere (Starzl and Terblanche 1979) and is discussed 
in Chapter S. Suffice it to say that the events of regen-
eration are enormously complex and although insulin is 
undoubtedly of great importance in the process, its role 
may not be so overriding as it has been shown to be in the 
regulation of hepatocyte size, organelle preservation and 
function. 
SUMMARY 
In all species so far studied, including man, portacaval 
shunt causes the same changes in liver morphology, 
including hepatocyte atrophy, fatty infiltration, deglyco-
genation, depletion and disorganization of the rough endo-
plasmic reticulum (RER) and its lining polyribosomes, and 
variable but less specific damage to other organelles. Many 
and perhaps all hepatic biosynthetic processes are quickly 
depressed, largely secondary to the selective damage to the 
RER which is the 'factory' of the cell. 
These structural and metabolic changes in the liver after 
portacaval shunt are caused mainly by the diversion 
around the liver of multiple hepatotrophic substances in 
portal venous blood, of which endogenous insulin is the 
most important. The subtle but far reaching changes in 
hepatic function after portal diversion have made it poss-
ible to use portacaval shunt to palliate three inborn errors 
of metabolism (glycogen storage disease, familial hyper-
cholesterolaemia, and alpha -I-an ti trypsin deficiency). 
However, a far more specific method of treating these 
three diseases has been by liver transplantation (Chs. 118, 
119, 121) whereby the defective liver is replaced by a 
homograft of normal metabolic phenotype. 
Because of the harm caused to the liver by portal diver-
sion, the use of completely diverting portacaval shunts to 
treat complications of portal hypertension has been viewed 
with increasing disapproval in recent years. If portal diver-
sion must be done for the control of variceal haemorrhage, 
a selective procedure such as the Warren shunt (Ch. 113) 
is theoretically superior to the completely diverting shunts 
since some of the hepatopetal flow is thereby retained, 
assunng exposure of the liver to portal hepatotrophic 
substances. 
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